Archive | General RSS for this section

MAKE IT STOP – a documentary about Ewing sarcoma by the Ewing Cancer Foundation of Canada – debuts scheduled for Richmond Hill ON (Sept 23), Labrador City (Sept 7), St John’s NL (Sept 17) and Fall River NS (Sept 23). Richmond Hill debut features live music by Tom Corrigan

MAKE IT STOP. A DOCUMENTARY.

You are cordially invited to celebrate the Debut of our most recent project. Through this important 45 minute documentary, we will share with you the history of Ewing sarcoma, stories of people affected and hear from doctors and researchers in Canada.
It will move, inspire and educate you!

September 23rd, 2017
Cosmo Music (Cosmopolitan Music Hall)
10 Via Renzo Drive
Richmond Hill, ON

Introduction: 2:00
Film screening will begin at 2:30
Refreshments and live music by Tom Corrigan

There is no charge for admission, however donations are greatly appreciated.  Please say you’ll come and share this Debut experience with us.  RSVP at contact@ewingscancer.ca by September 1st.

We are also hosting Debuts in the following areas; contact contact@ewingscancer.ca  if you would like to attend.

  • Labrador City- Sept. 7th
  • ST. John’s NL Sept. 17th
  • Fall River NS Sept. 23rd

Stay-tuned for funding and registration information for the C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology” educational workshop (04-Nov-2017, BC)

C17 “Next Generation of Early Phase Trials: Moving the Bar in Pediatric Oncology” educational workshop will be held on Saturday, 4 November 2017 in Vancouver, BC. The workshop is in response to the C17 DVL needs assessment that was completed last year; members from all C17 DVL sites and PROFYLE clinical site leads are encouraged to attend.

The workshop is a full day, pre-session workshop at the CCRA Canadian Cancer Research Conference. We hope that most attendees at our workshop will take the opportunity to attend the full conference as well.

The workshop will be designed to educate investigators on traditional models of early phase trials as well as newer approaches to drug development. We will also cover regulatory, ethical, advocacy and access aspects of early phase trials. The workshop will proved education, discussions, panels and time for questions.

If our fundraising is successful, our goal is to help provide some funding to C17 DVL participating centres to allow investigators and senior research staff to attend.

Registration will be live next week.

CAN YOU RECOGNIZE THE SYMPTOMS OF THE DICER1 SYNDROME? New DICER1 online resource physicians and patients, including variant maps, biobanking instructions and genetic testing. www.dicer1syndrome.ca

With over 50 years of combined research experience, clinician-researchers Dr. William Foulkes and Dr. David Malkin, are pleased to introduce a new resource for patients and healthcare professionals interested in learning more about DICER1 syndrome. Until now, our research has contributed to allowing caregivers recognize the major features of the syndrome, counsel families about the mutation status in their families, and offer surveillance for certain conditions that can occur in those carrying DICER1 mutations. However, due to the rarity of DICER1 syndrome and related tumors, the study of DICER1 syndrome has been limited by the number of cases which occur. This Canadian research network will work to provide an international resource for the dissemination of the information that has been learned about DICER1 syndrome (available in English, French, and Spanish), a DICER1 sample database available for researchers at no cost, and a tool for broadening our reach for case and specimen collection. Please visit our website (www.dicer1syndrome.ca) or contact Evan Weber (evan.weber2@mail.mcgill.ca) for more information.

2016 C17 HR Survey has been extended to the end of Sunday May 8.

If you cannot find your survey invitation, or if you would like to edit/complete your survey but did not write down your return code, contact Leah.Young2@ahs.ca.

Thank you to those that have responded so far.  The overall response rate is currently 69% for physicians, 100% for clinical associates and 76% for residents/fellows.  Results will be presented at the C17 AGM this June in Montreal.

Who has responded to the 2016 HR Survey so far? 39% of Attending Physicians, 40% of Clinical Associates and 27% of Residents/Fellows. Contact C17 if you cannot locate your invitation.

Every two years the C17 Human Resources Committee surveys the 17 Canadian Pediatric Hematology/Oncology divisions to help plan for staffing needs.  It is crucial that all peds hem/onc trained attending physicians, clinical associates, and non-attending physicians, as well as fellows/residents training in peds hem/onc complete this survey.

If you have not received an invitation to this survey, or if you know of a peds hem/onc trained fellow/resident obtaining additional training in a different area, please contact leah.young2@ahs.ca

Results of the survey will be posted at the C17 AGM in Montreal this June.

All physicians trained or training in peds hem/onc should have received an invitation to contribute to the 2016 C17 Human Resources Survey

Every two years the C17 Human Resources Committee surveys the 17 Canadian Pediatric Hematology/Oncology divisions to help plan for staffing needs.  It is crucial that all peds hem/onc trained attending physicians, clinical associates, and non-attending physicians, as well as fellows/residents training in peds hem/onc complete this survey.

If you have not received an invitation to this survey, or if you know of a peds hem/onc trained fellow/resident obtaining additional training in a different area, please contact leah.young2@ahs.ca

Results of the survey will be posted at the C17 AGM in Montreal this June.

C17 is measuring academic clinical trial accruals in Canada as part of 3CTN. If your study is eligible and not on the portfolio, please contact C17.

3CTN is an initiative to increase participation in academic oncology clinical trials in Canada (www.3ctn.ca).  As part of this project, C17 is tracking enrollment on pediatric clinical trials that are eligible for the 3CTN portfolio, and we would like to ensure that we have included all eligible studies.  We are aware of studies that we sponsor (e.g., COG, TACL),  but for other studies we rely on information from you, the researchers.

Are you aware of a study pediatric oncology study that meets the criteria below, please contact Leah in the C17 Council office (leah.young2@ahs.ca).

  • intervention study
  • open at more than one site in Canada (second site does not need to be a pediatric oncology/hematology centre)
  • not sponsored by industry

Note that a CTA is not required for eligibility, but a study would have to be listed on clinicaltrials.gov to go on the 3CTN portfolio.

 

 

Public funding for MRD testing recommended by Ontario Health Technology Advisory Committee

The Ontario Health Technology Advisory Committee has recently recommended public funding for MRD evaluations for children with ALL to the Ontario Ministry of Health and Long Term Care (MOHLTC).  This information may be of interest and use to those of you in provinces which do not yet provide access to publicly funded MRD evaluations for your ALL patients.

http://www.hqontario.ca/evidence/publications-and-ohtac-recommendations/ohtac-recommendations/ohtac-mrd

The complete recommendation document can be found at:

www.hqontario.ca/Portals/0/documents/eds/ohtas/recommendation-mrd-1603-en.pdf

The economic analysis can be found at: 

www.hqontario.ca/Portals/0/Documents/eds/ohtas/economic-analysis-mrd-1603-en.pdf